Evidence map›Paper›PMID 40933610›Full record

ReviewFrontiers in drug delivery2025

Strategies for delivering drugs across the blood-brain barrier for the treatment of neurodegenerative diseases.

Xiaopei Zhang, Manfei Fu, Yuanfei Wang, Tong Wu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Retinoic acid in health and disease.Signal transduction and targeted therapy · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiaopei ZhangShandong Key Laboratory of Medical and Health Textile Materials, Collaborative Innovation Center for Eco-textiles of Shandong Province and the Ministry of Education, College of Textiles and Clothing, Qingdao University, Qingdao, China.
Manfei FuMedical Research Center, The Affiliated Hospital of Qingdao University, Qingdao Medical College, Qingdao University, Qingdao, China.
Yuanfei WangQingdao Stomatological Hospital Affiliated to Qingdao University, Qingdao, China.
Tong WuShandong Key Laboratory of Medical and Health Textile Materials, Collaborative Innovation Center for Eco-textiles of Shandong Province and the Ministry of Education, College of Textiles and Clothing, Qingdao University, Qingdao, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The blood-brain barrier (BBB) restricts development of drug delivery systems for brain, which hinders the potential applications of numerous pharmaceutical agents for treating central nervous system (CNS) diseases. A number of drug delivery systems have been developed to enhance the capacity of drugs to cross BBB. A detailed introduction of the structure and function of BBB was given based on the mechanism of BBB, while comparing with the pathological changes of BBB in neurodegenerative diseases (NDDs), including activation of endothelial cells, the loose of tight junction and increase of BBB permeability. The liposomes, polymer nanoparticles and other novelty approaches for treating NDDs were summarized. Here, we provide a novel perspective to classify the strategies of drug delivery system as passive targeting and active targeting according to their mechanisms. The potential of clinical translational for drug delivery systems in NDDs was explored and underscored the imperative of safety and verification through clinical trials. In summary, this review proposed current developments of drug delivery systems and discussing the potentials of drug delivery systems in clinical translational which bring new breakthroughs for treating NDDs.

Indexed as

blood-brain barrierdrug deliverynanocarriersneurodegenerative diseasestargeted delivery

Identifiers

PMID40933610
PMCPMC12417466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.